Kymera Therapeutics Inc. (KYMR), a clinical-stage biopharmaceutical company developing targeted protein degradation to deliver novel small molecule protein degrader medicines, looks ahead to sharing data from its two oncology programs, KT-413 and KT-333, in the second half of this year.
from RTT - Top Story https://ift.tt/pZmFhEv
via IFTTT
from RTT - Top Story https://ift.tt/pZmFhEv
via IFTTT
Comments
Post a Comment